Hornung R S, Gould B A, Jones R I, Sonecha T N, Raftery E B
Am J Cardiol. 1983 May 1;51(8):1323-7. doi: 10.1016/0002-9149(83)90306-5.
The action of nifedipine tablets was examined in 17 patients with essential hypertension focusing particularly on the profile of blood pressure (BP) reduction over 24 hours resulting from both twice-daily and once-daily therapy (dose range 40 to 120 mg daily). This new formulation of nifedipine has a more prolonged and lower peak plasma level than an equivalent dose of nifedipine capsules. Our patients were fully ambulant and studied by continuous intraarterial recording techniques. BP responses during isometric and dynamic exercise testing were also observed. Within-patient comparisons of consecutive mean hourly systolic and diastolic BP showed a highly significant effect from twice-daily therapy (p less than 0.001) for nearly the entire day. Also, significantly lower BP was maintained during isometric and dynamic exercise. Mean hourly heart rates were not significantly altered. The profile of action of the single morning dose was initially similar, but its efficacy diminished from 6 P.M. to 8 A.M. on the following day. Side effects were not unduly troublesome and did not cause any patient withdrawals. Four patients developed mild ankle edema. Two others had facial flushing. Nifedipine given twice daily in tablet form, therefore, is an effective antihypertensive drug capable of lowering BP consistently over 24 hours in ambulant patients and during formal exercise testing. We suggest that this agent may be useful as initial therapy for systemic hypertension, although the tablets are not as yet widely available.
对17例原发性高血压患者进行了硝苯地平片的疗效研究,特别关注每日两次和每日一次治疗(剂量范围为每日40至120毫克)导致的24小时血压降低情况。这种新剂型的硝苯地平比等量剂量的硝苯地平胶囊具有更长时间且更低的血浆峰值水平。我们的患者可以完全自由活动,并通过连续动脉内记录技术进行研究。还观察了等长运动和动态运动测试期间的血压反应。患者自身连续每小时平均收缩压和舒张压的比较显示,每日两次治疗在几乎一整天内都有高度显著的效果(p小于0.001)。此外,在等长运动和动态运动期间血压显著降低。每小时平均心率没有明显改变。单次晨起剂量的作用情况最初相似,但其疗效在次日下午6点至上午8点有所下降。副作用并不十分麻烦,也没有导致任何患者退出研究。4例患者出现轻度踝部水肿。另外2例有面部潮红。因此,硝苯地平片每日两次给药是一种有效的抗高血压药物,能够在活动患者以及正式运动测试期间持续24小时降低血压。我们建议这种药物可作为系统性高血压的初始治疗药物,尽管这种片剂尚未广泛供应。